Drugs / WF10
WF10
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002119 | — | HIV infectious disease | Oxo Chemie GmbH | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04372355 | Jun 2019 → Apr 2020 | ulcer of lower limbs | Srinakharinwirot University | Completed | No outcome recorded |
| Phase 2 | NCT01586468 | Mar → Sep 2010 | allergic rhinitis | Nuvo Research Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00996463 | Jan → Sep 2010 | — | Waisenmedizin e. V. Promoting Access to Essential Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00002152 | — | HIV infectious disease | Oxo Chemie GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00002244 | — | HIV infectious disease | Oxo Chemie GmbH | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07096830 | Aug 2025 → Jul 2026 overdue | chronic ulcer of skin | Fazeelat Bibi | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WF 10 | “A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection” NCT00002119 ↗ |
| Known as | chlorite | “A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency...” PMID 25420793 ↗ Nov 2014 |
| Known as | DAC N-055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00996463 ↗ |
| Known as | Oxoferin | “Topical Tetrachlorodecaoxide (TCDO/Oxoferin)” NCT07096830 ↗ |
| Known as | TCDO | “A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection” NCT00002119 ↗3“Topical Tetrachlorodecaoxide (TCDO/Oxoferin)” NCT07096830 ↗ “WF10 (TCDO) Intravenous Solution” NCT00002244 ↗ “WF 10 (TCDO)” NCT00002152 ↗ |
| Known as | Tetrachlorodecaoxide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07096830 ↗ |
| Modality | Other / unclassified | “the chlorite-based drug” NCT04372355 ↗ |
| Route | Intravenous | “TCDO is a solution delivered through a vein.” NCT00002152 ↗ |